Compound Tropicamide Eye Drops

This product is composed of tropicamide and phenylephrine hydrochloride. Tropicamide has atropine-like parasympathetic nerve inhibitory effect, which can cause mydriasis and accommodation paralysis after drug absorption, while phenylephrine hydrochloride has sympathetic nerve excitatory effect, which manifests as mydriasis and local vasoconstriction after absorption.

Each bottle contains 25 mg of tropicamide and 25 mg of phenylephrine hydrochloride.

This product is a colorless or slightly yellow clear liquid.

Mydriatic drugs. Mydriatic and accommodative paralytic drugs for examination.

Generally, 0.5% tropicamide and 0.5% phenylephrine hydrochloride mixed eye drops are commonly used in clinical practice. The combination of the two drugs has a synergistic mydriasis effect, reduces the dosage of the drug and reduces adverse reactions. 1. Mydriasis examination: This product is dripped into the conjunctival sac, 1 drop at a time, and the second drop is dripped after an interval of 5 minutes. This product begins to dilate the pupil 5 to 10 minutes after eye drops, and the pupil is dilated to the maximum in 15 to 20 minutes. After about an hour and a half, the pupil begins to shrink, and the pupil returns to the level before the drop of the drug in 5 to 10 hours. 2. Refractive examination: Use this product to drip into the eye once every 5 minutes, for 4 consecutive drops, and a refractive examination can be performed after 20 minutes. Considering the existence of residual accommodation, it is not suitable for mydriasis optometry for children under 12 years old.

This product has not yet conducted a clear investigation on the frequency of adverse reactions in the use results survey. If systemic symptoms occur, the drug should be discontinued. 1. Serious adverse reactions: shock, allergic-like symptoms: shock and allergic-like symptoms may occur, so full observation is required. If symptoms such as erythema, rash, dyspnea, hypotension, eyelid edema, etc. are found, the drug should be discontinued and properly handled. 2. Other adverse reactions: When adverse reactions are found, appropriate measures such as discontinuation of drug administration should be taken. Type Frequency Frequency Unknown Allergic Blepharitis (redness and swelling of the eyelids, etc.), blepharodermatitis, itching Conjunctivitis (conjunctival congestion, edema, secretions, etc.), corneal epithelial dysfunction, increased intraocular pressure Others Thirst, facial flushing, increased heart rate, increased blood pressure.

It is contraindicated in patients with unoperated angle-closure glaucoma.

Precautions for children: Since systemic adverse reactions are prone to occur when used by children, they should be fully observed and used with caution. In particular, there have been reports of bradycardia and respiratory arrest in premature infants. They should be fully observed and use should be stopped immediately if abnormalities are found. Appropriate treatment is recommended. The best method is to dilute the product before use as needed. Precautions for pregnancy and lactation: It should only be used when its therapeutic benefits outweigh the risks. The safety of medication during pregnancy has not yet been determined. Precautions for the elderly: Generally, the physiological functions of the elderly are reduced, and attention should be paid.

Concomitant use with monoamine oxidase inhibitors or tricyclic antidepressants can cause a significant increase in blood pressure.

Keep away from light, tightly closed, in a cool place.

5ml: Tropicamide 25mg, Phenylephrine Hydrochloride 25mg

24 months

Changchun Dirui Pharmaceutical Co., Ltd.

• Founded in:

  1998-08-04

• Address:

  No. 639, Maoxiang Street, Changchun High-tech Industrial Development Zone

• Tax NO.:

  912201017025392978

• Registered Funds:

  45 million yuan

• Website:

  Log in to view

• Email:

  Log in to view